Latest stories on CLRB
Cellectar’s iopofosine case study shows complete response over 8 years
The Fly64 · neutralproduct/pr
Claris Biotherapeutics to Host Virtual KOL Event on Positive CSB-001 Data and the Unmet Need in Limbal Stem Cell Deficiency (LSCD)
Business Insider58 · neutralproduct/pr
Claris Biotherapeutics to Host Virtual KOL Event on Positive CSB-001 Data and the Unmet Need in Limbal Stem Cell Deficiency (LSCD)
GlobeNewswire58 · neutralproduct/pr
Claris Biotherapeutics Releases Positive CSB-001 Clinical Proof-of-Concept Data in Limbal Stem Cell Deficiency at AAO 2026 Annual Meeting
GlobeNewswire74 · bullishproduct/pr
Claris Biotherapeutics Releases Positive CSB-001 Clinical Proof-of-Concept Data in Limbal Stem Cell Deficiency at AAO 2026 Annual Meeting
Business Insider74 · bullishproduct/pr
Cellectar Biosciences to present data from Phase 2 CLOVER WaM trial
The Fly59 · neutralproduct/pr
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
The Motley Fool56 · neutralearnings
Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)
The Fly47 · neutralearnings
Cellectar targets mid-2027 accelerated approval NDA for iopofosine in WM, backed by up to $140M financing
Seeking Alpha67 · bullishproduct/pr
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Cellectar Biosciences, Inc. (CLRB) files 8-K
SEC 8-K50 · neutralgeneral
Cellectar Biosciences GAAP EPS of -$0.57 misses by $0.05
Seeking Alpha34 · bearishearnings
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Business Insider56 · neutralearnings
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
GlobeNewswire56 · neutralearnings
Cellectar Biosciences Q2 2026 Earnings Preview
Seeking Alpha50 · neutralearnings
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
Business Insider50 · neutralgeneral
Cellectar Biosciences, Inc. (CLRB) files 8-K
SEC 8-K50 · neutralgeneral
Cellectar Biosciences Bets on Iopofosine Breakthrough
TipRanks56 · neutralproduct/pr